Venture Catalysts Secures 9.6x Return on Exit from Pee Safe After OrbiMed-Led $32M Series C Round
Venture Catalysts has exited its stake in India's prominent women's hygiene and wellness brand Pee Safe.
The exit was facilitated through Pee Safe's recent $32 million Series C funding round led by global healthcare investor OrbiMed, finalized in January 2026.
Record-Breaking Investor Returns
Venture Catalysts achieved an impressive 9.6x return on invested capital and a 30.53% XIRR from the transaction.
This success highlights the lucrative potential in India's fast-growing direct-to-consumer personal care sector.
Pee Safe's Remarkable Growth Story
Launched in 2017, Pee Safe pioneered intimate hygiene solutions addressing a critical gap in women's wellness products.
The brand now reaches over 50,000 offline retail outlets across more than 100 cities nationwide.
Prior to this round, Pee Safe had cumulatively raised about $13.55 million, bringing total funding to roughly $45.55 million.
The new capital will accelerate product innovation, distribution expansion, and market penetration.
Experts view this development as a milestone for gender-specific health brands in emerging markets.
Venture Catalysts' profitable exit signals increasing maturity and investor confidence in Indian startups.
Future Prospects and Industry Impact
With OrbiMed's backing, Pee Safe is poised to dominate the women's hygiene category and explore international opportunities.
Such high-return exits encourage more venture capital inflows into health and wellness ventures.
